Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
Medicenna (OTCQX: MDNAF, TSX: MDNA) will present updated clinical data for MDNA11 from the Phase 1/2 ABILITY-1 study at the ESMO Immuno-Oncology Congress 2025 in London on December 10-12, 2025. The presentation by Dr. André Mansinho covers an interim analysis of MDNA11 as a monotherapy and in combination with pembrolizumab in advanced solid tumors.
Presentation title: ABILITY-1, a phase 1/2 of MDNA11, a next-generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors: interim analysis. A copy of the presentation will be posted on the company’s Events and Presentations page after the congress.
Medicenna (OTCQX: MDNAF, TSX: MDNA) presenterà dati clinici aggiornati su MDNA11 dallo studio di fase 1/2 ABILITY-1 al Congresso ESMO Immuno-Oncology 2025 a Londra dal 10 al 12 dicembre 2025. La presentazione del dottor André Mansinho copre un’analisi intermedia di MDNA11 come monoterapia e in combinazione con pembrolizumab in tumori solidi avanzati.
Titolo della presentazione: ABILITY-1, una fase 1/2 di MDNA11, un agonista IL-2 di prossima generazione, da solo o con pembrolizumab in tumori solidi avanzati: analisi intermedia. Una copia della presentazione sarà pubblicata nella pagina Eventi e Presentazioni dell’azienda dopo il congresso.
Medicenna (OTCQX: MDNAF, TSX: MDNA) presentará datos clínicos actualizados de MDNA11 del estudio de fase 1/2 ABILITY-1 en el Congreso ESMO Immuno-Oncology 2025 en Londres del 10 al 12 de diciembre de 2025. La presentación del Dr. André Mansinho cubre un análisis interino de MDNA11 como monoterapia y en combinación con pembrolizumab en tumores sólidos avanzados.
Título de la presentación: ABILITY-1, una fase 1/2 de MDNA11, un agonista IL-2 de próxima generación, solo o con pembrolizumab en tumores sólidos avanzados: análisis interino. Se publicará una copia de la presentación en la página de Eventos y Presentaciones de la empresa después del congreso.
Medicenna (OTCQX: MDNAF, TSX: MDNA)은 MDNA11에 대한 1/2상 ABILITY-1 연구의 업데이트된 임상 데이터를 런던에서 열리는 2025년 ESMO 면역항암제 학회에서 2025년 12월 10-12일에 발표할 예정입니다. Dr. André Mansinho의 발표는 고형암에서 단독요법으로서의 MDNA11과 pembrolizumab과의 병용에 대한 중간 분석을 다룹니다.
발표 제목: ABILITY-1, MDNA11의 1/2상 연구, 차세대 IL-2 작용제, 단독 또는 pembrolizumab과 함께 고형암에서의 중간 분석. 학회가 끝난 후 회사의 이벤트 및 발표 페이지에 발표 자료의 사본이 게시될 예정입니다.
Medicenna (OTCQX: MDNAF, TSX: MDNA) présentera des données cliniques mises à jour sur MDNA11 issues de l’étude de phase 1/2 ABILITY-1 lors du Congrès ESMO Immuno-Oncology 2025 à Londres du 10 au 12 décembre 2025. La présentation du Dr. André Mansinho couvre une analyse intermédiaire de MDNA11 en monothérapie et en association avec le pembrolizumab dans des tumeurs solides avancées.
Titre de la présentation : ABILITY-1, une phase 1/2 de MDNA11, un agoniste IL-2 de prochaine génération, seul ou avec pembrolizumab dans des tumeurs solides avancées : analyse intermédiaire. Une copie de la présentation sera publiée sur la page Événements et Présentations de l’entreprise après le congrès.
Medicenna (OTCQX: MDNAF, TSX: MDNA) wird aktualisierte klinische Daten zu MDNA11 aus der Phase-1/2-Studie ABILITY-1 beim ESMO Immuno-Oncology Congress 2025 in London vom 10. bis 12. Dezember 2025 präsentieren. Die Präsentation von Dr. André Mansinho behandelt eine Zwischenanalyse von MDNA11 als Monotherapie und in Kombination mit Pembrolizumab bei fortgeschrittenen soliden Tumoren.
Präsentations-Titel: ABILITY-1, eine Phase-1/2-Studie von MDNA11, ein next-generation IL-2-Agonist, allein oder mit Pembrolizumab bei fortgeschrittenen soliden Tumoren: Zwischenanalyse. Eine Kopie der Präsentation wird nach dem Kongress auf der Seite des Unternehmens Veranstaltungen und Präsentationen veröffentlicht.
Medicenna (OTCQX: MDNAF, TSX: MDNA) ستقدم بيانات علاجية منطلقة محدثة لـ MDNA11 من دراسة المرحلة 1/2 ABILITY-1 في المؤتمر ESMO Immuno-Oncology Congress 2025 في لندن خلال الفترة من 10 إلى 12 ديسمبر 2025. العرض الذي سيقدمه الدكتور أندريه مانشينو يغطي تحليلًا وسطياً لـ MDNA11 كعلاج أحادي و/أو بالت overlapping مع pembrolizumab في أورام صلبة متقدمة.
عنوان العرض: ABILITY-1، تجربة المرحلة 1/2 لـ MDNA11، محفز IL-2 من الجيل التالي، وحده أو مع pembrolizumab في أورام صلبة متقدمة: تحليل وسيط. سيتم نشر نسخة من العرض على صفحة فعاليات وعروض الشركة بعد المؤتمر.
Medicenna (OTCQX: MDNAF, TSX: MDNA) 将在伦敦举行的 ESMO Immuno-Oncology Congress 2025 上发布来自 ABILITY-1 研究的 MDNA11 的更新临床数据，时间为 2025 年 12 月 10-12 日。Dr. André Mansinho 的演讲将涵盖 MDNA11 作为单药治疗以及与 pembrolizumab 联合治疗在晚期实体肿瘤中的中期分析。
演讲题目：ABILITY-1，MDNA11 的 I/II 期研究，一种下一代 IL-2 激动剂，单药或与 pembrolizumab 联合治疗在晚期实体肿瘤中的中期分析。大会结束后，公司的“活动与演讲”页面将发布演示文稿的副本。
- None.
- None.
TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that updated MDNA11 clinical data will be presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 taking place December 10-12, 2025, in London, United Kingdom.
Updated clinical data from the Phase 1/2 ABILITY-1 Study evaluating MDNA11, an emerging best-in-class IL-2 therapy, as a monotherapy and in combination with pembrolizumab, will be presented by Dr. André Mansinho, a principal investigator of the study.
Details for the presentations are as follows:
Title: ABILITY-1, a phase 1/2 of MDNA11, a next-generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors: interim analysis
Presenter: Dr. André Mansinho, MD MSc, Assistant Professor, Faculty of Medicine, University of Lisbon
Date: December 10, 2025
Following the conclusion of the ESMO Immuno-Oncology 2025 Congress, a copy of the presentation will be available on the “Events and Presentations” page of Medicenna’s website.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s first-in-class targeted PD-1 x IL-2 bispecific, MDNA113, is in development for solid tumors and was designed using the Company’s proprietary BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) platforms. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.
For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts, such as statements on the therapeutic potential and safety profile of MDNA11. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor/Media Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
(416) 964-5442
ir@medicenna.com
FAQ
When will Medicenna (MDNAF) present MDNA11 data at ESMO Immuno-Oncology Congress 2025?
What specific data will Medicenna present for MDNA11 (MDNAF) at ABILITY-1?
Who will present the ABILITY-1 MDNA11 results for Medicenna (MDNAF) at ESMO 2025?
How can investors access Medicenna’s (MDNAF) MDNA11 presentation after ESMO Immuno-Oncology 2025?
Which trial phase is ABILITY-1 for MDNA11 that Medicenna (MDNAF) will report at ESMO 2025?
